|
業務類別
|
Biotechnology |
|
業務概覽
|
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel smallmolecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients. |
| 公司地址
| Emmy Noetherweg 2, Leiden, NLD, 2333 BK |
| 電話號碼
| +31 712036410 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pharvaris.com |
| 員工數量
| 129 |
| Dr. Stefan Abele, PhD |
Chief Technical Operations Officer |
-- |
02/04/2026 |
| Ms. Annick Deschoolmeester |
Chief Human Resources Officer |
-- |
02/04/2026 |
| Ms. Anna Nijdam, M.Sc. |
Head, Strategic Finance and Principal Accounting Officer |
-- |
02/04/2026 |
| Dr. Anne Lesage, PhD |
Chief Early Development Officer |
-- |
02/04/2026 |
| Dr. Peng Lu, M.D.,PhD |
Chief Medical Officer |
-- |
02/04/2026 |
| Dr. Wim Souverijns, PhD |
Chief Commercial Officer |
-- |
02/04/2026 |
| Mr. Berndt Modig |
Chief Executive Officer and Executive Director |
-- |
02/04/2026 |
| Mr. David W. Nassif, J.D. |
Chief Financial Officer and Chief Legal Officer |
-- |
02/04/2026 |
|
|
| Dr. David P. Meeker,M.D. |
Independent Director |
02/04/2026 |
| Dr. Robert Glassman, M.D. |
Independent Director |
02/04/2026 |
| Dr. Elisabeth Bjork, M.D.,PhD |
Independent Director |
02/04/2026 |
| Ms. Viviane Monges |
Independent Director |
02/04/2026 |
| Mr. Hans Schikan, Pharm.D. |
Independent Director |
02/04/2026 |
| Mr. Berndt Modig |
Chief Executive Officer and Executive Director |
02/04/2026 |
|
|
|
|
